Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.

Longeveron Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MIAMI, JULY 23, 2026 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN) A CLINICAL STAGE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPY FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THAT DEBORAH D. ASCHEIM, M.D.

DEBORAH D. ASCHEIM, M.D. ELECTED TO LONGEVERON BOARD OF DIRECTORS

POSTER PRESENTATION AT THE 2026 ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) ENTITLED LAROMESTROCEL STABILIZES BRAIN INFLAMMATION IN KEY ALZHEIMER'S DISEASE GRAY AND WHITE MATTER REGIONS AS ASSESSED USING FREE WATER MRI PRESENTED AT JULY 13TH IN PERSON POSTER PRESENTATION SESSION RESULTS SUPPORT A CLINICALLY RELEVANT AND LONG-LASTING ANTI-INFLAMMATORY MECHANISM OF ACTION OF LAROMESTROCEL IN GRAY AND WHITE MATTER OF THE BRAIN, INDICATE POTENTIAL BLOOD BIOMARKER CORRELATES WITH CLINICAL OUTCOMES, AND SUPPORT CONTINUED CLINICAL DEVELOPMENT OF LAROMESTROCEL FOR ALZHEIMER'S DISEASE LONGEVERON HAS RECEIVED U.S. FDA RMAT DESIGNATION FOR ITS ALZHEIMER'S DISEASE PROGRAM AND HAS ALIGNED ON A PHASE 3 STUDY DESIGN MIAMI, JULY 13, 2026 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPY FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THAT ADDITIONAL ANALYSIS OF DATA FROM THE PHASE 2A CLINICAL TRIAL EVALUATING ITS STEM CELL THERAPY LAROMESTROCEL IN MILD ALZHEIMER'S DISEASE (AD) IS BEING PRESENTED IN A POSTER PRESENTATION AT THE 2026 ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC), BEING HELD JULY 12-15, 2026 IN LONDON, UNITED KINGDOM AND ONLINE. RESULTS PRESENTED IN LAROMESTROCEL STABILIZES BRAIN INFLAMMATION IN KEY ALZHEIMER'S DISEASE GRAY AND WHITE MATTER REGIONS AS ASSESSED USING FREE WATER MRI PROVIDE SUPPORT FOR A CLINICALLY RELEVANT AND DURABLE ANTI-INFLAMMATORY MECHANISM OF ACTION OF LAROMESTROCEL IN GRAY AND WHITE MATTER AND INDICATE POTENTIAL BLOOD BIOMARKER CORRELATES.

LONGEVERON ANNOUNCES PRESENTATION OF CLINICAL DATA AT THE 2026 ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) THAT INDICATE ITS CELLULAR THERAPY LAROMESTROCEL REDUCED NEUROINFLAMMATION IN PATIENTS WITH ALZHEIMER'S DISEASE

MS. WASHBURN HAS OVER 20 YEARS OF EXPERIENCE IN LEADERSHIP ROLES IN THE PHARMACEUTICAL AND BIOTECH SECTORS CORPORATE FOCUS ON DELIVERING TOP-LINE RESULTS FROM THE PHASE 2B CLINICAL TRIAL EVALUATING ITS STEM CELL THERAPY IN HYPOPLASTIC LEFT HEART SYNDROME (HLHS), ANTICIPATED IN THE THIRD QUARTER OF 2026 MIAMI, JULY 06, 2026 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN) A CLINICAL STAGE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPY FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THAT THE COMPANY HAS APPOINTED MARIE WASHBURN TO THE COMPANY'S EXECUTIVE LEADERSHIP TEAM IN THE ROLE OF SENIOR VICE PRESIDENT AND CHIEF FINANCIAL OFFICER (CFO), PRINCIPAL FINANCIAL OFFICER AND PRINCIPAL ACCOUNTING OFFICER, EFFECTIVE JULY 13, 2026. SHE SUCCEEDS LISA LOCKLEAR WHO, AS PREVIOUSLY ANNOUNCED, IS STEPPING DOWN TO PURSUE BOARD OPPORTUNITIES AND OTHER PROFESSIONAL AND PERSONAL INTERESTS.

LONGEVERON APPOINTS MARIE WASHBURN AS CHIEF FINANCIAL OFFICER

MIAMI, JUNE 18, 2026 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPY FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THAT ADDITIONAL ANALYSIS OF DATA FROM THE PHASE 2A CLINICAL TRIAL EVALUATING ITS STEM CELL THERAPY LAROMESTROCEL IN MILD ALZHEIMER'S DISEASE HAS BEEN ACCEPTED FOR POSTER PRESENTATION AT THE 2026 ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC), TO BE HELD JULY 12-15, 2026 IN LONDON, UNITED KINGDOM AND ONLINE. POSTER PRESENTATION (EXHIBIT HALL) DATE: MONDAY, JULY 13, 2026 TIME: 7:30AM  4:15PM BST SESSION: IN-PERSON POSTERS TUESDAY; DRUG DEVELOPMENT: HUMAN TOPIC: LAROMESTROCEL IN MILD ALZHEIMER'S DISEASE: ADDITIONAL PHASE 2A CLINICAL DATA ANALYSIS  RESULTS FROM THE CLEAR MIND PHASE 2A CLINICAL TRIAL, WHICH SUPPORT THE THERAPEUTIC POTENTIAL OF LAROMESTROCEL IN THE TREATMENT OF MILD ALZHEIMER'S DISEASE AND PROVIDED EVIDENCE-BASED SUPPORT FOR FURTHER CLINICAL DEVELOPMENT, WERE PUBLISHED IN THE PEER-REVIEWED JOURNAL NATURE MEDICINE IN MARCH 2025.

NEW PHASE 2A CLINICAL DATA ANALYSIS OF STEM CELL THERAPY LAROMESTROCEL IN MILD ALZHEIMER'S DISEASE ACCEPTED FOR POSTER PRESENTATION AT THE 2026 ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC)

MIAMI, JUNE 09, 2026 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPY FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THAT THE COMPANY HAS BEEN GRANTED SMALL OR MEDIUM-SIZED ENTERPRISE (SME) STATUS BY THE EUROPEAN MEDICINES AGENCY (EMA), WHICH OFFERS SIGNIFICANT BENEFITS LEADING UP TO AND FOLLOWING DRUG REGULATORY APPROVAL. THE SME PROGRAM IS AN INITIATIVE BY THE EMA TO ADDRESS THE PARTICULAR NEEDS OF SMALL AND MEDIUM SIZE COMPANIES DEVELOPING MEDICINAL PRODUCTS IN EUROPE.

LONGEVERON GRANTED SMALL OR MEDIUM-SIZED ENTERPRISE (SME) STATUS BY THE EUROPEAN MEDICINES AGENCY (EMA)

LONGEVERON WILL PRESENT AT BIO 2026. CEO, CFO & BD WILL HOST MEETINGS TO EXPLORE PARTNERSHIP OPPORTUNITIES FOR ITS 4 STEM CELL THERAPY DEVELOPMET PROGRAMS.

LONGEVERON TO PRESENT AT BIO INTERNATIONAL CONVENTION 2026

MIAMI, MAY 20, 2026 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPY FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THAT THE COMPANY'S CHIEF EXECUTIVE OFFICER, STEPHEN WILLARD, ISSUED THE FOLLOWING LETTER TO LONGEVERON STOCKHOLDERS. DEAR FELLOW STOCKHOLDERS, I AM DELIGHTED TO JOIN LONGEVERON AT WHAT I BELIEVE IS AN EXTRAORDINARY TIME FOR THE COMPANY AND OUR STEM CELL THERAPY, LAROMESTROCEL (LOMECEL-B).

LONGEVERON ISSUES LETTER TO STOCKHOLDERS HIGHLIGHTING CORPORATE STRATEGY, STRATEGIC PARTNERING APPROACH AND 2026 KEY PRIORITIES

ON TRACK FOR AUGUST 2026 TOP-LINE RESULTS FROM PHASE 2B CLINICAL TRIAL (ELPIS II) EVALUATING LAROMESTROCEL AS A POTENTIAL ADJUNCT TREATMENT FOR HYPOPLASTIC LEFT HEART SYNDROME, A RARE PEDIATRIC DISEASE AND ORPHAN-DESIGNATED INDICATION CLOSED A PRIVATE PLACEMENT OF UP TO $30 MILLION, WITH $15 MILLION FUNDED IN THE INITIAL CLOSING, LED BY COASTLANDS CAPITAL WITH PARTICIPATION FROM JANUS HENDERSON INVESTORS AND OTHER HEALTHCARE FOCUSED FUNDS COMPANY TO HOST CONFERENCE CALL AND WEBCAST TODAY AT 4:30 P.M. ET MIAMI, MAY 13, 2026 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPY FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY REPORTED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2026 AND PROVIDED A BUSINESS UPDATE.

LONGEVERON ANNOUNCES 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

PHASE 2B CLINICAL TRIAL (ELPIS II) EVALUATING LAROMESTROCEL AS A POTENTIAL ADJUNCT TREATMENT FOR HLHS, A RARE PEDIATRIC DISEASE AND ORPHAN-DESIGNATED INDICATION DMC PERFORMED A RISK-BENEFIT ASSESSMENT, IDENTIFIED NO NEW SAFETY CONCERNS, AND RECOMMENDED CONTINUATION OF THE STUDY AS DESIGNED THROUGH COMPLETION THIS REVIEW REPRESENTS THE FINAL PLANNED INDEPENDENT SAFETY ASSESSMENT PRIOR TO COMPLETION OF THE TRIAL ELPIS II TOP-LINE TRIAL RESULTS ANTICIPATED IN AUGUST 2026 MIAMI, MAY 11, 2026 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPY FOR LIFE-THREATENING, RARE PEDIATRIC AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THAT THE INDEPENDENT DATA MONITORING COMMITTEE (DMC) HAS COMPLETED ITS FINAL PRESPECIFIED DATA REVIEW FOR THE ONGOING, FULLY ENROLLED, PHASE 2B CLINICAL TRIAL (ELPIS II) EVALUATING LAROMESTROCEL (LOMECEL-B) AS A POTENTIAL ADJUNCT THERAPY FOR HYPOPLASTIC LEFT HEART SYNDROME (HLHS). THE DMC BASED ITS REVIEW ON AVAILABLE DATA FOR ALL PARTICIPATING PATIENTS ENROLLED.

LONGEVERON ANNOUNCES INDEPENDENT DATA MONITORING COMMITTEE POSITIVE REVIEW AND RECOMMENDATION TO COMPLETE PHASE 2B STEM CELL THERAPY CLINICAL TRIAL IN HYPOPLASTIC LEFT HEART SYNDROME (HLHS)

MIAMI, MAY 08, 2026 (GLOBE NEWSWIRE) -- LONGEVERON INC. (NASDAQ: LGVN), A CLINICAL STAGE REGENERATIVE MEDICINE BIOTECHNOLOGY COMPANY DEVELOPING CELLULAR THERAPIES FOR LIFE-THREATENING AND CHRONIC AGING-RELATED CONDITIONS, TODAY ANNOUNCED THAT A CONSTRUCTIVE TYPE C MEETING WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA OR AGENCY) WAS HELD IN LATE MARCH, WITH THE FDA PROVIDING THEIR MEETING SUMMARY IN LATE APRIL, TO DISCUSS THE ONGOING DEVELOPMENT OF LAROMESTROCEL (LOMECEL-B), A PROPRIETARY, SCALABLE, ALLOGENEIC, INVESTIGATIONAL CELLULAR THERAPY CURRENTLY BEING EVALUATED IN A PHASE 2B CLINICAL TRIAL (ELPIS II) FOR HYPOPLASTIC LEFT HEART SYNDROME (HLHS). TOP-LINE RESULTS FROM THE RANDOMIZED, CONTROLLED PHASE 2B ELPIS II CLINICAL TRIAL ARE ANTICIPATED IN AUGUST 2026.

LONGEVERON ANNOUNCES CONSTRUCTIVE TYPE C MEETING WITH U.S. FDA AHEAD OF DATA READOUT FOR ELPIS II PHASE 2B CLINICAL TRIAL EVALUATING TREATMENT FOR HYPOPLASTIC LEFT HEART SYNDROME (HLHS)

Longeveron Inc.

LGVN

Price

Financial Reports

No items found.

Press Releases

Longeveron Inc.

LGVN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

LGVN